Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- AFH -24.5%, BW -22.8%, OPK -16.7%, FL -10.6%, AOBC -10.5%, JCP -9.4%, OMER-8.4%, AAC -7%, JD -6.4%, PSTG -4.6%, TNDM -4.1%, JWN -3.9%, PBYI -2.9%, FTSI-2.5%, RETA -1.6%, XRAY -0.5%, VMW -0.5%
Other news:
- SRRA -9.8% (commences common stock offering; size not disclosed)
- TYME -9.7% (prices 9 mln shares of common stock at $2.25 per share)
- RGR -4.3% (following AOBC results)
- RIO -1.7% (Australian Securities and Investments Commission takes action against Rio Tinto and its former CEO and CFO for misleading and deceptive conduct)
- RETA -1.6% ( reports top-line data from dose-escalation cohorts in motor study of omaveloxolone in patients with mitochondrial myopathies; did not improve peak work/walk distance versus placebo, which were the primary and secondary endpoints)
- BIIB -1.6% (Biogen and AbbVie (ABBV) withdraw Worldwide Marketing Authorizations for ZINBRYTA)
- VRX -1.6% (files mixed securities shelf (as expected); size not disclosed)
- MGM -0.8% (files mixed securities shelf offering), .
Analyst comments:
- PEGI -1.5% (downgraded to Mkt Perform from Outperform at Raymond James)
- WMT -1.3% (downgraded to Perform from Outperform at Oppenheimer)
- PRTK -1.2% (downgraded to Outperform from Strong Buy at Raymond James)
- OSK -1.1% (downgraded to Neutral from Outperform at Robert W. Baird)